Swissmedic published version 2.0 of its medical cannabis guidance on 1 June 2026, and two new sections now decide who in Switzerland can legally take delivery of your flower. Section 4.2.2 says the first buyer of cannabis from any grower, Swiss or foreign, must hold a licence to perform technical release of the active ingredient. Section 4.2.3 explains when a Swiss firm can import flower that a foreign manufacturer has already released.
Exporting cannabis to Switzerland in 2026 requires four approvals to line up:
- A Health Canada export permit for the shipment
- A Swissmedic import permit held by a Swiss company licensed to handle narcotics
- That company's establishment licence under the Therapeutic Products Act
- A named party that performs technical release under Article 7 of the Swiss Medicinal Products Licensing Ordinance
You apply for the first. Your Swiss buyer holds the second and third, and the fourth has to be agreed between you before anything ships. Miss it and your shipment has no legal place to land.
If you're still screening markets, start with our comparison of emerging cannabis import markets. If Switzerland is already on your shortlist, the detail below is what your Swiss counterparty's regulatory team will check first.
How Swissmedic controls cannabis imports in 2026
Switzerland moved medical cannabis into a new control regime on 1 August 2022. Cannabis with an average total THC content of 1.0% or more, intended for medical use, was reclassified from List d to List a of the Swiss narcotics lists. That put it under the same controls as morphine and removed the old requirement for an exceptional authorisation from the Federal Office of Public Health for each prescription.
Swissmedic now acts as the national cannabis agency required under the Single Convention on Narcotic Drugs. Two Swiss statutes apply at once: the Narcotics Act governs control and permits, and the Therapeutic Products Act governs manufacturing, quality and distribution. Your Swiss buyer needs licences under both.
| Permit or licence | Who holds it | Issued by |
|---|---|---|
| Export permit, per shipment | Canadian Licensed Producer | Health Canada |
| Import permit (Single Permit), per shipment | Swiss importer | Swissmedic Narcotics Division, via NDS-Web |
| Establishment licence to handle List a substances | Swiss importer | Swissmedic Narcotics Division, valid up to 5 years |
| Establishment licence under the Therapeutic Products Act | Swiss importer | Swissmedic Inspectorates and Licences |
| Technical release of the active ingredient | Swiss API manufacturer, or the foreign manufacturer | Article 7 of the Medicinal Products Licensing Ordinance |
On the Canadian side, the process runs through the export permit under the Cannabis Act, and Health Canada won't issue it without the importing country's permit in hand. Our step-by-step guide to the Health Canada export permit process covers that half. The Swiss importer also reports the date and quantity of every import to Swissmedic, and annual statements for controlled substances are due by the end of January.
Notice that none of the Swiss licences sit with you. Your real decision is which counterparty to pick, because their licence scope sets the limits of what your batch can legally become in Switzerland.
The technical release rule in Swissmedic's June 2026 update
Version 1.0 of the Swissmedic guidance didn't contain sections 4.2.2 or 4.2.3. The change history in the June 2026 guidance document shows both were added in version 2.0, nearly four years after the 2022 reform took effect. Some distribution-only importers took delivery as first buyers under the older reading. They now have two choices: extend their licence to cover activity 3.7, "technical release of active substances", or give up the first-buyer role.
The rule itself is simple. Cannabis used for medical purposes needs technical release, so the direct first buyer from a grower must hold a licence for active pharmaceutical ingredient (API) manufacturing. Swissmedic states this applies whether the grower sits in Switzerland or abroad. That sentence covers every Canadian LP shipping to Switzerland.
The Swiss two-route release test
Every Canadian batch bound for Switzerland travels one of two routes. Your Swiss buyer's regulatory team will decide which one, so ask before anything ships.
- Route A, grower material: your flower arrives unreleased, and the Swiss first buyer holds activity 3.7 and performs the technical release itself.
- Route B, released API: your flower arrives already GMP-released by a manufacturer holding a valid manufacturing authorisation from an authority that Swissmedic recognises. A second Swiss release isn't automatically required, though extra processing in Switzerland can trigger more quality control.
Here's where Canadian LPs tend to get stuck. A licence under the Cannabis Act proves you produce legally in Canada. It doesn't, on its own, show that you hold a manufacturing authorisation Swissmedic recognises. That's the Route B question, and a Swiss release team will want it answered on paper. Our guide to EU QP batch release covers the same question as it plays out inside the EU.
Pharmacies face a harder line. A Swiss pharmacy may not buy cannabis from a foreign grower at all. It can buy from a foreign manufacturer, but only after confirming GMP release and a recognised manufacturing authorisation.
Don't sign a Swiss supply agreement until your buyer names, in writing, the licence holder that performs Article 7 release and the route your batches will take. Everything else in the deal depends on that answer.
Quality evidence Swiss buyers ask for
Swiss law requires medicines to meet the pharmacopoeia, and for cannabis flower that now means the European Pharmacopoeia. Swissmedic's guidance confirms the Ph. Eur. monograph for cannabis flower took effect on 1 July 2024 and replaced the former Swiss monograph, Ph. Helv. CH 311. Swiss specifications for flower now match the ones EU importers test against, which is why the gaps we describe in EU retesting and COA differences apply here too.
Manufacturing herbal medicines in Switzerland falls under the GMP guide, including EU GMP Annex 7 on herbal medicinal products. Annex 7 points to the GACP guideline for cultivation. Swissmedic doesn't inspect or certify GACP, though. The buyer decides how far GACP applies and runs or commissions its own analyses, so your buyer's supplier qualification file becomes the real standard.
Where Swiss rules draw the GMP line
Swissmedic's guidance splits post-harvest work into two groups. Separating flower from stem, trimming and gentle pre-drying to prevent mould count as cultivation steps. Final drying, adjusting and analysing residual moisture to Ph. Eur. requirements, and primary and secondary packaging count as manufacturing under the Therapeutic Products Act. Our guide to cannabis water activity and moisture limits covers the numbers behind that moisture step. If you want Route B, your records for that second group need the same detail and sign-off as any GMP batch record.
Expect a Swiss regulatory team to ask for:
- A batch certificate of analysis from an ISO/IEC 17025 accredited laboratory, covering the Ph. Eur. monograph parameters
- Your GMP status and the authority that issued it
- Traceability from cultivation lot to shipped batch
- Drying, moisture and packaging records for the exported lot
- A signed quality agreement that assigns release responsibility
That last document does the most work. Our guide to cannabis quality agreements shows how to write release responsibility into it. Swiss buyers will read your COA closely, but the quality agreement is the document their release team signs off on.
What the Swiss medical cannabis market can absorb
Medical cannabis reaches Swiss patients mostly as magistral preparations made by pharmacies to a doctor's prescription. Swissmedic's guidance names Sativex as the only authorised medicine based on cannabis extract. Magistral preparations can't be imported or exported, so your flower enters Switzerland only as an active ingredient for a licensed Swiss company, never as a finished Swiss medicine.
Demand growth has been slow. Compulsory health insurance reimburses cannabis treatment only in exceptional cases. Doctors must also report treatment data to the Federal Office of Public Health through the MeCanna system, which is set to run until 2029. Prohibition Partners reported in 2025 that patient numbers hadn't risen substantially since the 2022 reform, citing administrative burden and restrictive reimbursement.
Promotion is closed too. The Therapeutic Products Act bans public advertising for medicines containing narcotics. For cannabis dispensed as a magistral preparation, Swissmedic says even advertising aimed at health professionals isn't permitted. Pharmacies may only state, in general terms, that they fill such orders. Demand for your flower in Switzerland will come through your partner's existing pharmacy and prescriber relationships.
Adult use won't change the picture in 2026. The FOPH pilot trials run on Swiss-produced cannabis, and the draft federal Cannabis Products Act went back to a parliamentary subcommission for revision in May 2026. Switzerland is a medical, pharmacy-led market in 2026. Plan for smaller volumes, longer qualification and a buyer who treats your documentation as seriously as your flower.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, growing indoor, hand-trimmed flower from refined genetics. Every batch carries ISO/IEC 17025 test data and full traceability from cultivation lot to shipment, and we hold export authorisation under the Cannabis Act. That's the documentation base a Swiss importer's release team starts from.
If you hold a Swiss List a licence and want a Canadian supply partner, talk to our export team before your next Single Permit application. The permits are the easy part. Agreeing on release is what takes time.
Frequently Asked Questions
Can a Canadian Licensed Producer export medical cannabis to Switzerland?
Yes. You need a Health Canada export permit matched to a Swissmedic import permit. The Swiss importer must be licensed to handle List a narcotics and hold an establishment licence under the Therapeutic Products Act. The shipment must also go to a buyer that performs technical release or can rely on a release you provide as a recognised manufacturer.
What is a Swissmedic Single Permit for cannabis?
A Single Permit is the Swissmedic import or export authorisation for one shipment of a controlled substance. The Swiss licence holder applies for it through NDS-Web, and the date and quantity of each import must be reported to Swissmedic.
Can a Swiss pharmacy buy cannabis flower directly from a Canadian producer?
Not from a foreign grower. A Swiss pharmacy can buy from a foreign manufacturer only if that manufacturer demonstrates GMP release and holds a valid manufacturing authorisation from an authority Swissmedic recognises.
Which pharmacopoeia applies to cannabis flower in Switzerland?
The European Pharmacopoeia. Its monograph for cannabis flower took effect on 1 July 2024 and replaced the former Swiss monograph, Ph. Helv. CH 311.
Can Canadian cannabis supply Switzerland's adult-use pilot trials?
No. The FOPH pilot trials run on cannabis produced in Switzerland. A draft national Cannabis Products Act was sent back to a parliamentary subcommission for revision in May 2026, so there is no adult-use import channel in 2026.
Does Swiss health insurance cover medical cannabis?
Only in exceptional cases. Compulsory health insurance does not routinely reimburse cannabis treatment, which is one reason Swiss patient numbers have grown slowly since the 2022 reform.
